ROYCE & ASSOCIATES LP - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$84,881,529
+10.0%
947,550
+4.6%
0.86%
+15.4%
Q2 2023$77,161,701
+10.5%
906,292
+7.4%
0.75%
+7.2%
Q1 2023$69,820,644
+7.5%
843,754
+2.2%
0.70%
+2.5%
Q4 2022$64,922,586
+0.2%
825,462
-5.6%
0.68%
-6.8%
Q3 2022$64,762,000
+18.1%
874,808
+3.9%
0.73%
+29.6%
Q2 2022$54,855,000
+14.6%
841,585
+11.1%
0.56%
+38.8%
Q1 2022$47,873,000
+27.5%
757,244
+6.9%
0.41%
+44.8%
Q4 2021$37,558,000
-45.9%
708,108
-28.1%
0.28%
-46.0%
Q3 2021$69,486,000
+73.3%
984,358
+63.6%
0.52%
+88.4%
Q2 2021$40,087,000
-22.9%
601,546
+28.4%
0.28%
-21.1%
Q1 2021$52,018,000
-26.8%
468,585
-21.7%
0.35%
-40.5%
Q4 2020$71,102,000
+39.6%
598,756
+2.6%
0.59%
+6.9%
Q3 2020$50,920,000
+15.3%
583,608
+18.3%
0.55%
+12.9%
Q2 2020$44,170,000
+17.7%
493,193
+31.0%
0.49%
-4.7%
Q1 2020$37,532,000
+982.9%
376,605
+1148.3%
0.51%
+1548.4%
Q4 2019$3,466,000
+100.2%
30,169
+56.3%
0.03%
+158.3%
Q2 2018$1,731,000
+18.3%
19,300
-3.5%
0.01%
+20.0%
Q1 2018$1,463,000
+12091.7%
20,000
+9515.4%
0.01%
Q4 2017$12,000
+9.1%
208
-16.5%
0.00%
Q3 2017$11,000
-99.9%
249
-99.9%
0.00%
-100.0%
Q3 2013$8,937,000
-34.1%
224,100
-31.7%
0.03%
-35.7%
Q2 2013$13,563,000328,0000.04%
Other shareholders
HAEMONETICS CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders